These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21490436)

  • 1. Borderline breast lesions: diagnostic challenges and clinical implications.
    Masood S; Rosa M
    Adv Anat Pathol; 2011 May; 18(3):190-8. PubMed ID: 21490436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interobserver reproducibility in the pathologic diagnosis of borderline ductal proliferative breast diseases].
    Wei B; Bu H; Zhu CR; Guo LX; Chen HJ; Zhao C; Zhang P; Chen DY; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):849-53. PubMed ID: 15573772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why the term 'low-grade ductal carcinoma in situ' should be changed to 'borderline breast disease': diagnostic and clinical implications.
    Masood S
    Womens Health (Lond); 2012 Jan; 8(1):57-62. PubMed ID: 22171775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
    Masood S; Loya A; Khalbuss W
    Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
    Bofin AM; Lydersen S; Hagmar BM
    Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Papillary lesions of the breast: selected diagnostic and management issues.
    Collins LC; Schnitt SJ
    Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
    Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
    Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyerplasia: correlations with surgical findings].
    Piubello Q; Montemezzi S; D'Atri C
    Pathologica; 2002 Dec; 94(6):299-305. PubMed ID: 12540993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
    Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
    Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses.
    Jakate K; De Brot M; Goldberg F; Muradali D; O'Malley FP; Mulligan AM
    Am J Surg Pathol; 2012 Apr; 36(4):544-51. PubMed ID: 22314186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic analysis of atypical lesions in image-guided core breast biopsies.
    Bonnett M; Wallis T; Rossmann M; Pernick NL; Bouwman D; Carolin KA; Visscher D
    Mod Pathol; 2003 Feb; 16(2):154-60. PubMed ID: 12591968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic immunohistochemistry of breast epithelial lesions].
    Balaton AJ; Guinebretière JM; Penault-Llorca F
    Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?
    Middleton LP; Grant S; Stephens T; Stelling CB; Sneige N; Sahin AA
    Mod Pathol; 2003 Feb; 16(2):120-9. PubMed ID: 12591964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotaxic fine needle aspiration cytology of clinically occult malignant and premalignant breast lesions.
    Bibbo M; Scheiber M; Cajulis R; Keebler CM; Wied GL; Dowlatshahi K
    Acta Cytol; 1988; 32(2):193-201. PubMed ID: 2831687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of ductal carcinoma in situ by the pathologist: current questions].
    Arnould L; Caron Y; Sigal-Zafrani B
    Ann Pathol; 2003 Dec; 23(6):534-46. PubMed ID: 15094591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of precancerous and high-risk mammary lesions.
    Bégin LR
    Can J Surg; 1985 May; 28(3):248-51. PubMed ID: 2986807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical ductal hyperplasia in breast core needle biopsies. Correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies.
    Renshaw AA; Cartagena N; Schenkman RH; Derhagopian RP; Gould EW
    Am J Clin Pathol; 2001 Jul; 116(1):92-6. PubMed ID: 11447758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center.
    Farshid G; Edwards S; Kollias J; Gill PG
    Mod Pathol; 2018 Mar; 31(3):395-405. PubMed ID: 29099502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology of high-risk breast lesions and ductal carcinoma in situ.
    Sewell CW
    Radiol Clin North Am; 2004 Sep; 42(5):821-30, v. PubMed ID: 15337418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy.
    Deshaies I; Provencher L; Jacob S; Côté G; Robert J; Desbiens C; Poirier B; Hogue JC; Vachon E; Diorio C
    Breast; 2011 Feb; 20(1):50-5. PubMed ID: 20619647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.